Ticker > Company >

Gennex Lab share price

Gennex Laboratories Ltd.

BSE: 531739 SECTOR: Pharmaceuticals & Drugs  66.89 K   247   24

11.34
+0.07 (0.62%)
BSE: Today, 03:34 PM

Price Summary

Today's High

₹ 11.5

Today's Low

₹ 11.01

52 Week High

₹ 29

52 Week Low

₹ 10.84

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

270.97 Cr.

Enterprise Value

212.61 Cr.

No. of Shares

23.89 Cr.

P/E

19.33

P/B

1.47

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  7.72

CASH

60.96 Cr.

DEBT

2.61 Cr.

Promoter Holding

19.83 %

EPS (TTM)

₹  0.59

Sales Growth

2.61%

ROE

9.68 %

ROCE

12.5%

Profit Growth

158.78 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year2.61%
3 Year3.85%
5 Year3.66%

Profit Growth

1 Year158.78%
3 Year42.96%
5 Year39.66%

ROE%

1 Year9.68%
3 Year8.82%
5 Year8.49%

ROCE %

1 Year12.5%
3 Year11.66%
5 Year11.29%

Debt/Equity

0.0158

Price to Cash Flow

-8.11

Interest Cover Ratio

13.7661

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 19.83 21.79
Mar 2025 18.42 23.87
Dec 2024 18.42 0.00
Sep 2024 18.42 0.00
Jun 2024 18.42 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 42.9576874179521% for the Past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 13.7661.
  • Company’s PEG ratio is 0.191407340683076.
  • The company has an efficient Cash Conversion Cycle of 32.7452 days.
  • Company has a healthy liquidity position with current ratio of 5.4536.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 16.752513001149.

 Limitations

  • The company has shown a poor revenue growth of 3.84562528643817% for the Past 3 years.
  • Company has negative cash flow from operations of -33.4279.
  • Promoter pledging is high as 21.79%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 21.33 26.51 27.35 23.28 25.64
Total Expenditure 18.41 20.98 21.78 23.06 22.27
Operating Profit 2.92 5.53 5.57 0.22 3.38
Other Income 2.46 0 0 2.87 2.26
Interest 0.3 0.47 0.41 0.54 0.59
Depreciation 0.17 0.05 0.2 0.23 0.2
Exceptional Items 0 0 0 -0.15 0
Profit Before Tax 4.92 5.01 4.96 2.18 4.85
Tax 0.75 0.85 0.75 0.68 0.7
Profit After Tax 4.17 4.16 4.21 1.5 4.15
Adjusted EPS (Rs) 0.18 0.18 0.19 0.07 0.18

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 55.62 59.65 61.21 65.1 66.8
Total Expenditure 52.37 53.12 55.84 60.52 54.38
Operating Profit 3.25 6.53 5.38 4.58 12.42
Other Income 0.95 0.52 1.38 3.4 4.3
Interest 0.75 0.74 0.88 1.23 1.16
Depreciation 1 0.88 0.79 0.74 0.81
Exceptional Items 0.11 -0.37 0 0 0
Profit Before Tax 2.55 5.06 5.09 6.01 14.75
Tax 0.69 1.02 1.17 1.45 2.96
Net Profit 1.86 4.04 3.92 4.56 11.8
Adjusted EPS (Rs.) 0.14 0.3 0.3 0.26 0.52

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 12.65 12.65 12.65 18.02 22.74
Total Reserves 23.2 27.24 31.35 61 148.01
Borrowings 0 0 0 1.29 1.76
Other N/C liabilities 0.41 0.17 0 -0.14 -0.23
Current liabilities 20.86 19.02 24.21 15.91 32.82
Total Liabilities 57.13 59.08 68.21 96.08 205.11
Assets
Net Block 14.93 14.13 13.7 15.18 15.83
Capital WIP 0 0 0 0 1.38
Intangible WIP 0 0 0 0 0
Investments 7.01 7.01 7.01 8.26 8.26
Loans & Advances 0.22 1.57 0.32 0.48 0.64
Other N/C Assets 0 0 0 0 0
Current Assets 34.97 36.38 47.18 72.16 178.99
Total Assets 57.13 59.08 68.21 96.08 205.11
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 2.55 5.06 5.28 6.01 14.87
Adjustment 1.68 1.57 2.57 -0.74 -1.8
Changes in Assets & Liabilities -5.9 -6.54 -0.1 -19.73 -45.4
Tax Paid 0 -1.53 -1.11 0 -1.09
Operating Cash Flow -1.67 -1.44 6.64 -14.45 -33.43
Investing Cash Flow -0.22 -0.02 -1.26 -0.77 0.93
Financing Cash Flow -0.35 1.62 1.87 21.35 79.01
Net Cash Flow -2.23 0.16 7.24 6.14 46.51

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 18.42 18.42 18.42 18.42 19.83
india securities brooking... 0.03 0.03 0.03 0.03 0.03
premier fiscal services p... 16.50 16.50 16.50 16.50 17.95
prudential investment lim... 0.02 0.02 0.02 0.02 0.02
subhash chand bhura trust... 0.34 0.34 0.34 0.34 0.33
vab ventures limited 1.51 1.51 1.51 1.51 1.48
vinod baid 0.02 0.02 0.02 0.02 0.02
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 81.58 81.58 81.58 81.58 80.17
enforcement directorate r... - - - - 0.03
jms mines & minerals priv... 3.47 3.47 3.47 3.47 3.41
llp 0.34 0.43 0.52 0.57 0.90
miraj digvijay shah - - - 0.18 0.17
rajababu sampatrao bandel... 1.51 1.51 1.51 1.51 1.48
sanjay kumar 1.64 1.64 1.64 1.64 1.61
brij bhushan agarwal 1.98 1.98 - - -
hemant kumar jain 1.76 1.76 - - -
sumitra devi agarwal 1.98 1.98 - - -
vidya tradecon private li... 2.20 2.20 - - -
ridhi sidhi distributor (... 1.16 - - - -
sumita talwar 1.86 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2023
Annual Report 2023
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Gennex Lab - Quaterly Results 14 Aug, 5:28 PM Gennex Lab - Quaterly Results 14 Aug, 5:28 PM Gennex Laboratories informs about outcome of board meeting 4 Jul, 4:39 PM Gennex Laboratories informs about disclosures 24 Mar, 4:32 PM Gennex Laboratories informs about disclosure 24 Mar, 11:41 AM Gennex Laboratories informs about disclosure 20 Mar, 5:03 PM Gennex Laboratories informs about compliance certificate 25 Oct, 2:54 PM Gennex Lab - Quaterly Results 14 Aug, 5:27 PM Gennex Lab - Quaterly Results 30 May, 8:09 PM Gennex Laboratories informs about newspaper publication 16 Feb, 5:29 PM Gennex Lab - Quaterly Results 14 Feb, 5:27 PM Gennex Lab - Quaterly Results 14 Feb, 5:27 PM Gennex Laboratories informs about updates 13 Dec, 3:03 PM Gennex Lab - Quaterly Results 14 Nov, 12:00 PM Gennex Lab - Quaterly Results 14 Nov, 12:00 PM Gennex Laboratories gets WHO-GMP Certificate from Government of Telangana 11 Jul, 2:45 PM Gennex Laboratories informs about closure of trading window 1 Jul, 4:00 PM Gennex Laboratories informs about outcome of board meeting 31 May, 10:36 AM Gennex Laboratories informs about acquisition 2 Mar, 4:56 PM Gennex Laboratories informs about disclosure 23 Nov, 10:57 AM Gennex Laboratories informs about board meeting 19 Sep, 5:10 PM Gennex Laboratories informs about disclosure 16 Sep, 3:35 PM Gennex Laboratories informs about disclosure 16 Sep, 12:01 PM Gennex Laboratories informs about allotment of equity shares 26 Aug, 4:22 PM Gennex Laboratories informs about disclosure 11 Aug, 4:50 PM Gennex Laboratories informs about disclosure 26 Jul, 4:50 PM Gennex Laboratories informs about disclosures 26 Jul, 4:23 PM Gennex Laboratories informs about trading window closure 1 Jul, 5:05 PM Gennex Laboratories informs about trading window closure 6 Apr, 2:18 PM Gennex Laboratories to raise funds through permissible modes 29 Mar, 11:22 AM Gennex Lab - Quaterly Results 14 Feb, 5:41 PM Gennex Laboratories submits certificate 12 Jan, 5:14 PM Gennex Laboratories to make Deccan Remedies as subsidiary 5 Jan, 2:29 PM Gennex Laboratories informs about compliance certificate 30 Apr, 1:28 PM Gennex Laboratories informs about board meeting 3 Feb, 4:29 PM Gennex Laboratories informs about appointment of non-executive director 21 Dec, 1:34 PM Gennex Laboratories informs about board meeting 18 Dec, 5:04 PM Gennex Laboratories informs about related party transaction 3 Dec, 1:46 PM Gennex Laboratories informs about compliance certificate 19 Oct, 1:43 PM Gennex Laboratories informs about outcome of board meeting 14 Aug, 4:51 PM Gennex Laboratories gets WHO-GMP Certificate from Drug Control Administration 4 Jun, 10:13 AM

Gennex Lab Stock Price Analysis and Quick Research Report. Is Gennex Lab an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Gennex Lab. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Gennex Lab has a PE ratio of 19.3284472473155 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Gennex Lab has ROA of 7.8342% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Gennex Lab has a Current ratio of 5.4536.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Gennex Lab has a ROE of 9.6822%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Gennex Lab has a Debt to Equity ratio of 0.0158 which means that the company has low proportion of debt in its capital.

  • Sales growth: Gennex Lab has reported revenue growth of 2.6124% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Gennex Lab for the current financial year is 18.5914385645772%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Gennex Lab is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Gennex Lab is Rs 0.5867. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Gennex Lab in Ticker for free. Also, one can get the intrinsic value of Gennex Lab by using Valuation Calculators, which are available with a Finology ONE subscription. 

Gennex Lab FAQs

Q1. What is Gennex Lab share price today?
Ans: The current share price of Gennex Lab is Rs 11.34.

Q2. What is the market capitalisation of Gennex Lab?
Ans: Gennex Lab has a market capitalisation of Rs 270.966662316 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Gennex Lab?
Ans: The PE ratio of Gennex Lab is 19.3284472473155 and the P/B ratio of Gennex Lab is 1.4696543590674, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Gennex Lab share?
Ans: The 52-week high share price of Gennex Lab is Rs 29, and the 52-week low share price of Gennex Lab is Rs 10.84.

Q5. Does Gennex Lab pay dividends?
Ans: Currently, Gennex Lab does not pay dividends. Dividend yield of Gennex Lab is around 0%.

Q6. What are the face value and book value of Gennex Lab shares?
Ans: The face value of Gennex Lab shares is Rs 1, while the book value per share of Gennex Lab is around Rs 7.7161. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Gennex Lab?
Ans: Gennex Lab has a total debt of Rs 2.6053156 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Gennex Lab?
Ans: The ROE of Gennex Lab is 9.6822% and ROCE of Gennex Lab is 12.4957%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Gennex Lab a good buy for the long term?
Ans: The Gennex Lab long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Gennex Lab undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Gennex Lab appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Gennex Lab’s financials?
Ans: You can review Gennex Lab’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Gennex Lab
X